论文部分内容阅读
作者采用白细胞介素2(IL2)或(和)LAK细胞治疗6例多发性骨髓瘤(MM).年龄54 72岁.IgG-k型3例,IgG-λ型1例,IgA-λ型1例,本周氏蛋白(BJP)-λ型1例.ⅡA期1例,ⅢA期4例,ⅢB期1例.治前均曾接受多种治疗,包括米尔法兰、环磷酰胺、长春新碱、甲基亚硝脲、甲基苄肼、阿霉素、强的松龙及β或γ干扰素.3例MM患者单独接受IL2治疗,剂量分别为例1、3.3×10~5U/日×5天,例2、1×10~6U/日×5天及例
Six patients with multiple myeloma (MM) were treated with interleukin 2 (ILK) or (and) LAK cells, aged 54 72. Three patients were IgG-k, one was IgG-λ and one was IgA-λ For example, this week’s protein (BJP) -λ type in 1 case.ⅡA period in 4 cases, Ⅲ A period in 4 cases, Ⅲ B period in 1. Before treatment have received a variety of treatments, including Mill flange, cyclophosphamide, Changchun new Methyl nitrosourea, procarbazine, doxorubicin, prednisolone, and beta or gamma interferon.3 Three patients with MM received IL2 alone at doses of 1, 3.3 × 10-5 U / day × 5 days, case 2, 1 × 10 ~ 6U / day × 5 days and cases